<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Veru Inc — News on 6ix</title>
<link>https://6ix.com/company/veru-inc</link>
<description>Latest news and press releases for Veru Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 09 Mar 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/veru-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835d2a678dffbe2df1203ab.webp</url>
<title>Veru Inc</title>
<link>https://6ix.com/company/veru-inc</link>
</image>
<item>
<title>Veru Enrolls First Patient in Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss</title>
<link>https://6ix.com/company/veru-inc/news/veru-enrolls-first-patient-in-phase-2b-plateau-clinical-trial-of-enobosarm-and-semaglutide-combination-for-high-quality-weight-loss</link>
<guid isPermaLink="true">https://6ix.com/company/veru-inc/news/veru-enrolls-first-patient-in-phase-2b-plateau-clinical-trial-of-enobosarm-and-semaglutide-combination-for-high-quality-weight-loss</guid>
<pubDate>Mon, 09 Mar 2026 04:00:00 GMT</pubDate>
<description>-- The Phase 2b study to assess enobosarm’s ability to preserve lean mass, physical function, and bone as well as burn more fat to produce greater quality and</description>
</item>
<item>
<title>Veru to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference</title>
<link>https://6ix.com/company/veru-inc/news/veru-to-present-at-the-oppenheimer-36th-annual-healthcare-life-sciences-conference</link>
<guid isPermaLink="true">https://6ix.com/company/veru-inc/news/veru-to-present-at-the-oppenheimer-36th-annual-healthcare-life-sciences-conference</guid>
<pubDate>Thu, 19 Feb 2026 13:30:00 GMT</pubDate>
<description>MIAMI, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced that Mitchell Steiner, M.D., Chairman, President and Chief Executive Officer of Veru, will present at the upcoming virtual Oppenheimer 36th Annual Healthcare Life Sciences Conference on Thursday, February 26, 2026 at 3:20 pm – 3:50 pm ET. A live webcast will be</description>
</item>
<item>
<title>Veru Reports Fiscal 2026 First Quarter Financial Results and Clinical Program Progress</title>
<link>https://6ix.com/company/veru-inc/news/veru-reports-fiscal-2026-first-113000910</link>
<guid isPermaLink="true">https://6ix.com/company/veru-inc/news/veru-reports-fiscal-2026-first-113000910</guid>
<pubDate>Wed, 11 Feb 2026 11:30:00 GMT</pubDate>
<description>-- Phase 2b PLATEAU clinical trial evaluating enobosarm in combination with semaglutide in older patients with obesity on track to initiate this quarter— --Company to host conference call and webcast today at 8:00 a.m. ET-- MIAMI, FL, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced financial results for its fiscal 2</description>
</item>
<item>
<title>Veru to Report Fiscal 2026 First Quarter Financial Results on February 11th</title>
<link>https://6ix.com/company/veru-inc/news/veru-report-fiscal-2026-first-133000608</link>
<guid isPermaLink="true">https://6ix.com/company/veru-inc/news/veru-report-fiscal-2026-first-133000608</guid>
<pubDate>Wed, 04 Feb 2026 13:30:00 GMT</pubDate>
<description>MIAMI, FL, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced it will host a conference call and audio webcast on Wednesday, February 11, 2026, at 8:00 a.m. ET to discuss its fiscal 2026 first quarter financial results and to provide a business update. The audio webcast will be accessible under the Home page and Invest</description>
</item>
<item>
<title>Veru Reports Fiscal Year 2025 Financial Results and Clinical Program Progress</title>
<link>https://6ix.com/company/veru-inc/news/veru-reports-fiscal-2025-financial-113000511</link>
<guid isPermaLink="true">https://6ix.com/company/veru-inc/news/veru-reports-fiscal-2025-financial-113000511</guid>
<pubDate>Wed, 17 Dec 2025 11:30:00 GMT</pubDate>
<description>-- Following positive efficacy and safety results from Phase 2b QUALITY study, company received FDA regulatory clarity for enobosarm in combination with GLP-1 RA -- -- Incremental weight loss is an acceptable approvable primary endpoint with key secondary endpoints on physical function and body composition improvements -- -- Company plans to initiate Phase 2 PLATEAU clinical study in calendar Q1 2026 -- -- Post fiscal year end, company completed public offering for net proceeds of approximately</description>
</item>
<item>
<title>Veru to Report Fiscal Year 2025 Financial Results on December 17th</title>
<link>https://6ix.com/company/veru-inc/news/veru-report-fiscal-2025-financial-133000889</link>
<guid isPermaLink="true">https://6ix.com/company/veru-inc/news/veru-report-fiscal-2025-financial-133000889</guid>
<pubDate>Wed, 10 Dec 2025 13:30:00 GMT</pubDate>
<description>MIAMI, FL, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced it will host a conference call and audio webcast on Wednesday, December 17, 2025, at 8:00 a.m. ET to discuss its fiscal year 2025 financial results and to provide a business update. The audio webcast will be accessible under the Home page and Investors page</description>
</item>
<item>
<title>Veru to Present at The Society on Sarcopenia, Cachexia, and Wasting Disorders 18th International Conference and Regulatory and Clinical Trials Update Regulatory Workshop</title>
<link>https://6ix.com/company/veru-inc/news/veru-present-society-sarcopenia-cachexia-133000585</link>
<guid isPermaLink="true">https://6ix.com/company/veru-inc/news/veru-present-society-sarcopenia-cachexia-133000585</guid>
<pubDate>Thu, 04 Dec 2025 13:30:00 GMT</pubDate>
<description>MIAMI, FL, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced multiple presentations at The Society on Sarcopenia, Cachexia, and Wasting Disorders (SCWD) 18th International Conference, and the SCWD’s Regulatory and Clinical Trials Update Regulatory Workshop, both in Rome, Italy. 18th International Conference of the Soc</description>
</item>
<item>
<title>Veru to Present Two Abstracts at ObesityWeek 2025</title>
<link>https://6ix.com/company/veru-inc/news/veru-present-two-abstracts-obesityweek-123000227</link>
<guid isPermaLink="true">https://6ix.com/company/veru-inc/news/veru-present-two-abstracts-obesityweek-123000227</guid>
<pubDate>Fri, 31 Oct 2025 12:30:00 GMT</pubDate>
<description>MIAMI, FL, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced the presentation of two abstracts at ObesityWeek 2025 taking place November 4-7, 2025, in Atlanta, Georgia. Poster presentation name: Enobosarm Reduced Body Weight and Fat Regain and Preserved Lean Mass After Discontinuing SemaglutidePresenter: Steven B. Hey</description>
</item>
<item>
<title>Veru Announces Pricing of $25 Million Public Offering</title>
<link>https://6ix.com/company/veru-inc/news/veru-announces-pricing-25-million-120000390</link>
<guid isPermaLink="true">https://6ix.com/company/veru-inc/news/veru-announces-pricing-25-million-120000390</guid>
<pubDate>Thu, 30 Oct 2025 12:00:00 GMT</pubDate>
<description>MIAMI, FL, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, announced today the pricing of an underwritten public offering of (i) 1,400,000 shares of its common stock, (ii) pre-funded warrants to purchase up to 7,000,000 shares of its common stock, and (iii) accompanying Series A warrants to purchase up to 8,400,000 shares of common</description>
</item>
<item>
<title>Veru Announces Proposed Public Offering</title>
<link>https://6ix.com/company/veru-inc/news/veru-announces-proposed-public-offering-200100171</link>
<guid isPermaLink="true">https://6ix.com/company/veru-inc/news/veru-announces-proposed-public-offering-200100171</guid>
<pubDate>Wed, 29 Oct 2025 20:01:00 GMT</pubDate>
<description>MIAMI, FL, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, announced today that it has commenced an underwritten public offering of shares of its common stock (or pre-funded warrants to purchase its common stock in lieu thereof) and in either case, accompanying Series A warrants and Series B warrants to purchase shares of its commo</description>
</item>
<item>
<title>Veru Announces Successful FDA Meeting Providing Regulatory Clarity for Enobosarm for Muscle Preservation in Combination with GLP-1 RA for Greater Weight Loss in the Treatment of Obesity</title>
<link>https://6ix.com/company/veru-inc/news/veru-announces-successful-fda-meeting-123000737</link>
<guid isPermaLink="true">https://6ix.com/company/veru-inc/news/veru-announces-successful-fda-meeting-123000737</guid>
<pubDate>Tue, 23 Sep 2025 12:30:00 GMT</pubDate>
<description>MIAMI, FL, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced a successful meeting with FDA providing regulatory clarity for enobosarm, a selective androgen receptor modulator, as a muscle preservation drug product candidate in combination with GLP-1 RA for greater weight loss for the treatment of obesity. Highlights</description>
</item>
<item>
<title>Veru Reports Fiscal 2025 Third Quarter Financial Results and Clinical Program Progress</title>
<link>https://6ix.com/company/veru-inc/news/veru-reports-fiscal-2025-third-103000071</link>
<guid isPermaLink="true">https://6ix.com/company/veru-inc/news/veru-reports-fiscal-2025-third-103000071</guid>
<pubDate>Tue, 12 Aug 2025 10:30:00 GMT</pubDate>
<description>--Company reported positive efficacy and safety data from Phase 2b QUALITY study showing enobosarm added to semaglutide led to preservation of muscle, greater fat loss, and fewer gastrointestinal side effects compared to semaglutide alone-- --Company reported positive efficacy and safety data from Phase 2b QUALITY Maintenance Extension study showing enobosarm significantly reduced body weight regain, prevented fat regain, and preserved lean mass after semaglutide discontinuation-- --Company has</description>
</item>
<item>
<title>Veru Announces Selection of Novel Modified Release Oral Enobosarm Formulation for Chronic Weight Loss Management Following Pharmacokinetic Clinical Study</title>
<link>https://6ix.com/company/veru-inc/news/veru-announces-selection-novel-modified-123000696</link>
<guid isPermaLink="true">https://6ix.com/company/veru-inc/news/veru-announces-selection-novel-modified-123000696</guid>
<pubDate>Mon, 11 Aug 2025 12:30:00 GMT</pubDate>
<description>MIAMI, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced selection of a novel modified release oral formulation for enobosarm, a selective androgen receptor modulator, for chronic weight loss management, following confirmation of pharmacokinetic endpoints in a clinical study. The single dose, open label pilot study ev</description>
</item>
<item>
<title>Veru Announces Reverse Stock Split</title>
<link>https://6ix.com/company/veru-inc/news/veru-announces-reverse-stock-split-123000857</link>
<guid isPermaLink="true">https://6ix.com/company/veru-inc/news/veru-announces-reverse-stock-split-123000857</guid>
<pubDate>Wed, 06 Aug 2025 12:30:00 GMT</pubDate>
<description>MIAMI, FL, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced that it will effect a 1-for-10 reverse stock split of its shares of common stock. The reverse stock split will become effective at 11:59 pm CT on Friday, August 8, 2025. The Company’s common stock is expected to begin trading on the Nasdaq Capital Market und</description>
</item>
<item>
<title>Veru to Report Fiscal 2025 Third Quarter Financial Results on August 12th</title>
<link>https://6ix.com/company/veru-inc/news/veru-report-fiscal-2025-third-123000775</link>
<guid isPermaLink="true">https://6ix.com/company/veru-inc/news/veru-report-fiscal-2025-third-123000775</guid>
<pubDate>Tue, 05 Aug 2025 12:30:00 GMT</pubDate>
<description>MIAMI, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced it will host a conference call and audio webcast on Tuesday, August 12, 2025, at 8:00 a.m. ET to discuss its fiscal 2025 third quarter financial results and to provide a business update. The audio webcast will be accessible under the Home page and Investors page</description>
</item>
<item>
<title>Veru to Participate in the 2025 BTIG Virtual Biotech Conference</title>
<link>https://6ix.com/company/veru-inc/news/veru-participate-2025-btig-virtual-123000614</link>
<guid isPermaLink="true">https://6ix.com/company/veru-inc/news/veru-participate-2025-btig-virtual-123000614</guid>
<pubDate>Tue, 22 Jul 2025 12:30:00 GMT</pubDate>
<description>MIAMI, FL, July 22, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced that the company will be participating in one-on-one meetings and a fireside chat presentation with investors at the 2025 BTIG Virtual Biotech Conference taking place from July 29-30, 2025. About Veru Inc.Veru is a late clinical stage biopharmaceutical compa</description>
</item>
<item>
<title>Veru Reports Positive Results from Phase 2b QUALITY and Maintenance Extension Study Showing Enobosarm Significantly Reduced Body Weight Regain, Prevented Fat Regain, and Preserved Lean Mass After Semaglutide Discontinuation</title>
<link>https://6ix.com/company/veru-inc/news/veru-reports-positive-results-phase-123000078</link>
<guid isPermaLink="true">https://6ix.com/company/veru-inc/news/veru-reports-positive-results-phase-123000078</guid>
<pubDate>Tue, 24 Jun 2025 12:30:00 GMT</pubDate>
<description>--During the Maintenance Period of 12 weeks after discontinuing semaglutide (GLP-1 receptor agonist), placebo group regained 43% of body weight that was previously lost during Phase 2b QUALITY study; on average, enobosarm 3mg significantly reduced body weight regain by 46% and completely prevented fat regain compared to placebo-- --The enobosarm treated groups showed up to 93% greater fat loss and 100% lean mass preservation compared to the placebo group at the end of the study-- --Enobosarm mon</description>
</item>
<item>
<title>Veru to Participate in the Virtual BTIG Obesity Health Forum</title>
<link>https://6ix.com/company/veru-inc/news/veru-participate-virtual-btig-obesity-123000882</link>
<guid isPermaLink="true">https://6ix.com/company/veru-inc/news/veru-participate-virtual-btig-obesity-123000882</guid>
<pubDate>Wed, 11 Jun 2025 12:30:00 GMT</pubDate>
<description>MIAMI, FL, June 11, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced the company will be participating in one-on-one meetings and a fire side chat presentation with investors at the virtual BTIG Obesity Health Forum on June 18, 2025. About Veru Inc.Veru is a late clinical stage biopharmaceutical company focused on developing</description>
</item>
<item>
<title>Veru Reports Positive Safety Results from Phase 2b QUALITY Study: Enobosarm Added to Semaglutide Led to Greater Fat Loss, Preservation of Muscle, and Fewer Gastrointestinal Side Effects Compared to Semaglutide Alone</title>
<link>https://6ix.com/company/veru-inc/news/veru-reports-positive-safety-results-103000600</link>
<guid isPermaLink="true">https://6ix.com/company/veru-inc/news/veru-reports-positive-safety-results-103000600</guid>
<pubDate>Wed, 28 May 2025 10:30:00 GMT</pubDate>
<description>--Phase 2b QUALITY clinical study topline safety data shows that the enobosarm + semaglutide combination had a positive safety profile compared to semaglutide alone-- --Based on Phase 2b QUALITY trial efficacy and safety data, enobosarm 3mg will advance as the proposed oral dose for the Phase 3 clinical program----Enobosarm 3mg + semaglutide combination had the added benefit of fewer gastrointestinal side effects (Diarrhea, Nausea, and GERD) compared to semaglutide alone-- --Enobosarm 3mg added</description>
</item>
<item>
<title>Veru Participates in a Virtual Investor KOL Connect Segment</title>
<link>https://6ix.com/company/veru-inc/news/veru-participates-virtual-investor-kol-132500733</link>
<guid isPermaLink="true">https://6ix.com/company/veru-inc/news/veru-participates-virtual-investor-kol-132500733</guid>
<pubDate>Thu, 08 May 2025 13:25:00 GMT</pubDate>
<description>-- Moderated discussion with preeminent obesity expert, Louis J. Aronne, MD, FACP and Mitchell Steiner, M.D., F.A.C.S, President, CEO, and Founder, of Veru -- MIAMI, FL, May 08, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced the release of a Virtual Investor KOL segment featuring Louis J. Aronne, MD, FACP. As part of the se</description>
</item>
</channel>
</rss>